HC Wainwright & Co.
Upgrade grade
B
Downgrade grade
C
HC Wainwright & Co. was founded in 1988 and has evolved into a diversified investment bank headquartered in New York with a strong presence across equity research, institutional sales, and corporate advisory services. The firm has established itself as a meaningful player in small and mid-cap equity coverage, with approximately 8,414 analyst ratings calls in our database, reflecting substantial depth in tracking US equities across multiple sectors. HC Wainwright has built particular expertise and recognition in healthcare, life sciences, and technology sectors, where they maintain dedicated analyst teams that follow both established companies and emerging growth opportunities. The firm has developed a distinctive reputation for its contrarian research perspectives and willingness to take independent positions on controversial or overlooked companies, earning respect from institutional investors who value their detailed fundamental analysis and sector expertise despite the firm's lower mainstream profile compared to larger bulge-bracket competitors.
Upgrades
95
74.74% win rate
· avg +6.56% D1
Downgrades
140
70.71% win rate
· avg -11.21% D1
Avg Gap — Upgrades
+6.93%
open vs prev close
Avg Gap — Downgrades
-9.74%
open vs prev close
Performance by Sector
| Sector | ↑ Win% | ↑ D1 | ↓ Win% | ↓ D1 |
|---|---|---|---|---|
| Healthcare | 76.12% (67) | +7.65% | 75.68% (111) | -13.96% |
Win Rate by Year
| Year | ↑ Win% | ↑ Calls | ↓ Win% | ↓ Calls |
|---|---|---|---|---|
| 2026 | — | — | 46.2% | 13 |
| 2025 | 73.3% | 30 | 72.7% | 33 |
| 2024 | — | — | 81.0% | 21 |
| 2023 | 58.3% | 12 | 85.7% | 14 |
| 2022 | — | — | 70.6% | 17 |
| 2021 | 82.4% | 17 | 61.5% | 13 |
| 2020 | — | — | 64.3% | 14 |
Recent Calls
| Date | Ticker | Company | Sector | Action | Grade Change | PT | Gap | D1 |
|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | IONS | Ionis Pharmaceuticals, Inc. | Healthcare | Maintains | Buy → Buy | — | +0.1% | -0.1% |
| Apr 30, 2026 | GMAB | Genmab A/S | Healthcare | Maintains | Buy → Buy | — | +1.3% | +1.6% |
| Apr 29, 2026 | AXGN | AxoGen, Inc. | Healthcare | Maintains | Buy → Buy | — | -1.1% | -0.5% |
| Apr 29, 2026 | RLAY | Relay Therapeutics, Inc. | Healthcare | Maintains | Buy → Buy | — | +1.1% | -3.5% |
| Apr 29, 2026 | BBIO | BridgeBio Pharma, Inc. | Healthcare | Maintains | Buy → Buy | — | -2.0% | +1.8% |
| Apr 28, 2026 | GROY | Gold Royalty Corp. | Basic Materials | Maintains | Buy → Buy | — | -2.8% | -3.1% |
| Apr 28, 2026 | CGEM | Cullinan Therapeutics, Inc. | Healthcare | Maintains | Buy → Buy | — | +1.1% | -3.3% |
| Apr 28, 2026 | CMPS | COMPASS Pathways plc | Healthcare | Maintains | Buy → Buy | — | -1.6% | -5.1% |
| Apr 27, 2026 | DWTX | Dogwood Therapeutics, Inc. | Healthcare | Maintains | Buy → Buy | — | -2.2% | -2.9% |
| Apr 27, 2026 | NRXP | NRx Pharmaceuticals, Inc. | Healthcare | Maintains | Buy → Buy | — | +1.7% | +3.1% |
| Apr 27, 2026 | ENTX | Entera Bio Ltd. | Healthcare | Maintains | Buy → Buy | — | +2.7% | +2.7% |
| Apr 27, 2026 | ACOG | Alpha Cognition Inc. Common Stock | Financial Services | Maintains | Buy → Buy | — | -1.6% | -6.3% |
| Apr 27, 2026 | CMPX | Compass Therapeutics, Inc. | Healthcare | Maintains | Buy → Buy | — | -64.8% | -64.4% |
| Apr 27, 2026 | PRLD | Prelude Therapeutics Incorporated | Healthcare | Maintains | Buy → Buy | — | +4.7% | -3.8% |
| Apr 27, 2026 | ITRG | Integra Resources Corp. | Basic Materials | Maintains | Buy → Buy | — | +0.0% | -2.7% |
| Apr 27, 2026 | URG | Ur-Energy Inc. | Energy | Maintains | Buy → Buy | — | -0.6% | +4.1% |
| Apr 27, 2026 | JBIO | Jade Biosciences, Inc. | Healthcare | Maintains | Buy → Buy | — | +3.2% | +7.5% |
| Apr 27, 2026 | NRIX | Nurix Therapeutics, Inc. | Healthcare | Maintains | Buy → Buy | — | -1.0% | -1.1% |
| Apr 27, 2026 | MIRM | Mirum Pharmaceuticals, Inc. | Healthcare | Maintains | Buy → Buy | — | +0.6% | +1.1% |
| Apr 27, 2026 | BBIO | BridgeBio Pharma, Inc. | Healthcare | Maintains | Buy → Buy | — | +3.5% | +1.7% |
| Apr 27, 2026 | BNTX | BioNTech SE | Healthcare | Maintains | Buy → Buy | — | +0.1% | -3.2% |
| Apr 24, 2026 | EVAX | Evaxion Biotech A/S | Healthcare | Maintains | Buy → Buy | — | +0.5% | -5.2% |
| Apr 24, 2026 | GUTS | Fractyl Health, Inc. Common Stock | Healthcare | Maintains | Buy → Buy | — | +1.5% | +6.7% |
| Apr 23, 2026 | CRVO | CervoMed Inc. | Healthcare | Maintains | Buy → Buy | — | +0.5% | -2.3% |
| Apr 23, 2026 | KYTX | Kyverna Therapeutics, Inc. | Healthcare | Maintains | Buy → Buy | — | -0.6% | -12.5% |